{'fraction_non_alphanumeric': 0.02781456953642384, 'fraction_numerical': 0.0, 'mean_word_length': 5.631578947368421, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hydergine in senile mental impairment.

Among gerontopsychiatric drugs, Hydergine is pharmacologically characterized by agonist action at central dopamine and serotonin receptors. This review presents a summary of the results obtained with Hydergine in numerous controlled trials in patients with senile mental impairment. Assessment was carried out by means of a rating scale (mainly the Sandoz Clinical Assessment Geriatric, or SCAG, scale), psychometric tests (e.g. the Nuremberg Geriatric Inventory, or NGI), and the EEG. Hydergine also lowers serum prolactin, though a correlation with clinical improvement has not been established as yet. In the discussion, the need for objective, measurable and precise indicators in gerontopsychiatry is stressed.